ArticleFrontiers in oncology2026
Internal validation of a residual thyroid recurrence model after PTC.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At present, the risk factors contributing to the recurrence of papillary thyroid carcinoma (PTC) in residual thyroid tissue post-surgery are not yet fully understood. This study sought to identify multivariable predictors (MVPs) associated with such recurrence and to develop a dynamic, individualized nomogram. The objective is to establish a stratification framework to inform precision "risk-intervention" decision-making for patients at elevated risk of recurrence. Methods: A cohort of 2,512 patients diagnosed with thyroid cancer and treated at the First Affiliated Hospital of Bengbu Medical University between January 2014 and December 2024 was analyzed. The cohort was stratified into a training set (n = 1,760) and a validation set (n = 752) using stratified random sampling with a 7:3 ratio. To address the class imbalance between recurrent and non-recurrent cases in the residual thyroid, the Random Over-Sampling Examples (ROSE) method was employed on the training set. Variable selection was conducted using univariate and multivariate logistic regression, LASSO regression, and standard stepwise regression based on the Akaike Information Criterion (AIC). A nomogram was subsequently developed by integrating the coefficients of the selected variables from the logistic regression model. The performance of the nomogram was assessed in both cohorts in terms of discrimination, calibration, and clinical utility. Results: In a study of 2,512 thyroid cancer patients who received primary treatment, 146 experienced recurrence in the remaining thyroid tissue. Using univariate and multivariate logistic regression and LASSO regression for feature selection, four independent predictors were identified for the final predictive model: maximum tumor diameter, number of metastatic lymph nodes, lymph node positivity rate, and age. The nomogram showed strong discriminatory ability, with an AUC of 0.7518 in the training set and 0.8347 in the validation set. It also demonstrated excellent calibration and clinical utility across all groups. The best cut-off value for the nomogram score to identify patients with residual thyroid recurrence was 0.245, with scores above this linked to a significantly worse postoperative outcome. Conclusions: We have developed and validated an innovative clinical prediction model specifically designed to assess the risk of recurrence in residual thyroid tissue. This model serves as a valuable tool for clinicians, facilitating personalized decision-making and representing a significant advancement in the postoperative management of papillary thyroid carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.